Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers A > Headlines for Angiotech Pharmaceuticals, Inc. > News item |
Merrill keeps Angiotech at buy
Angiotech Pharmaceuticals Inc. was maintained at its buy rating by Merrill Lynch analyst Hari Sambasivam. The company reported revenues of $97.7 million, including $43.0 million of Taxus royalties, compared to the analyst's estimate of $97.8 million in revenues and $40.9 million in Taxus royalties. Shares of the Toronto-based pharmaceutical company were down C$0.9, or 0.67%, at C$13.36, on volume of 159,226 shares versus the three-month running average of 211,677 shares. (Toronto: ANP)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.